Overview

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

Status:
Completed
Trial end date:
2018-04-21
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus
Tacrolimus